The Republican proposal, which now heads to the Senate, makes it so Utah health providers can no longer block someone from ...

The field of transfusion medicine has long sought effective alternatives to human blood, focusing increasingly on bio-synthetic blood substitutes and ...

Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...